Multicenter cooperative observational study of reactivation of hepatitis B virus caused by anticancer treatments for solid tumors
Not Applicable
- Conditions
- Solid tumor patients with seropositivity for HBsAg, or seronegativity for HBsAg and seropositivity for HBcAb and/or HBsAb, receiving first chemotherapy including neoadjuvant and adjuvant chemotherapy.
- Registration Number
- JPRN-UMIN000005369
- Lead Sponsor
- Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) During hemodialyis or planning to introuce hemodialyis. 2) Seropositivity to HCVAb 3) Seropositivity for HBsAb only with a history of HBV vaccination 4) Not eligible judged by investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rate of HBV reactivation Outcome of the patients in whom the HBV reactivation developed
- Secondary Outcome Measures
Name Time Method Investigation of the background of patients in whom the HBV reactivation developed Difference of outcome of the patients between obedience and non-obedience of Japanese guideline of HBV reactivation